Healthcare / Diagnostics & ResearchNYSE
$492.45
-0.06 (-0.01%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $6.9B · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$183.0B
P/E
27.1x
↑EV/EBITDA
18.7x
↑ROE
12.6%
↑Gross Margin
40.9%
↓Debt/Equity
0.74
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+8.8%
FCF CAGR
+9.1%
FCF margin
14.1%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $44.56B · net income $6.70B · FCF $6.29B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $44.56B | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B | $25.54B | $24.36B | $20.92B | $18.27B | $16.96B | $16.89B | $13.09B | $12.51B | $11.56B | $10.39B | $9.91B | $10.50B | $9.75B |
| Net Income | $6.70B | $6.70B | $6.33B | $6.00B | $6.95B | $7.73B | $6.38B | $3.70B | $2.94B | $2.23B | $2.02B | $1.98B | $1.89B | $1.27B | $1.18B | $1.33B | $1.04B | $850.3M | $980.9M | $748.4M |
| EBITDA | $11.51B | $11.51B | $11.54B | $11.08B | $11.94B | — | — | — | $6.05B | $4.99B | $4.22B | $4.02B | $4.19B | $2.61B | $2.47B | $2.11B | $1.93B | $1.76B | $2.02B | $1.73B |
| EPS | 17.74 | 17.74 | 16.53 | 15.45 | 17.63 | 19.46 | 15.96 | 9.17 | 7.24 | 5.59 | 5.09 | 4.92 | 4.71 | 3.48 | 3.21 | 3.46 | 2.53 | 2.01 | 2.25 | 1.69 |
| Gross Margin | 40.9% | 40.9% | 41.3% | 39.9% | 42.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 18.2% | 18.2% | 18.0% | 17.1% | 18.9% | 25.6% | 24.2% | 18.0% | 15.5% | 14.2% | 13.5% | 13.8% | 14.8% | 12.3% | 11.8% | 10.8% | 11.4% | 10.1% | 11.7% | 10.0% |
| Net Margin | 15.0% | 15.0% | 14.8% | 14.0% | 15.5% | 19.7% | 19.8% | 14.5% | 12.1% | 10.6% | 11.1% | 11.6% | 11.2% | 9.7% | 9.4% | 11.5% | 10.0% | 8.6% | 9.3% | 7.7% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 0.74 | 0.74 | 0.63 | 0.75 | 0.78 | 0.85 | 0.55 | 0.58 | 0.64 | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.53 | 1.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $6.29B | $6.29B | $7.27B | $6.93B | $6.91B | $6.79B | $6.82B | $4.05B | $3.79B | $3.50B | $2.81B | $2.52B | $2.19B | $1.73B | $1.72B | $1.43B | $1.25B | $1.46B | $1.16B | $1.31B |
| Returns | ||||||||||||||||||||
| ROE | 12.6% | 12.6% | 12.8% | 12.8% | 15.8% | 18.9% | 18.5% | 12.5% | 10.7% | 8.8% | 9.4% | 9.3% | 9.2% | 7.6% | 7.6% | 8.8% | 6.7% | 5.5% | 6.6% | 5.2% |
| Valuation | ||||||||||||||||||||
| P/E | 27.10 | 27.10 | 32.19 | 34.38 | 30.35 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 18.74 | 18.74 | 20.03 | 21.03 | 19.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.49 | 3.49 | 4.11 | 4.41 | 4.79 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 3.9% | 3.9% | 0.1% | -4.6% | — | 21.7% | 26.1% | 4.9% | 16.4% | 14.5% | 7.7% | 0.4% | 29.0% | 4.6% | 8.2% | 11.2% | 4.9% | -5.6% | 7.7% | — |
| EPS Growth | 7.3% | 7.3% | 7.0% | -12.4% | — | 21.9% | 74.0% | 26.7% | 29.5% | 9.8% | 3.5% | 4.5% | 35.3% | 8.4% | -7.2% | 36.8% | 25.9% | -10.7% | 33.1% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
35.1%
EPS terminal req.
$43.70
Spread vs growth
-27.7%
5Y implied EPS CAGR
24.4%
EPS terminal req.
$52.87
Spread vs growth
-17.1%
10Y implied EPS CAGR
17.0%
EPS terminal req.
$85.15
Spread vs growth
-9.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+22.6%
Start / end P/E
24.4x → 27.8x
EPS bridge
16.53 → 17.74
Residual
+1.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.